After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Recursion Pharmaceuticals Inc is $2.00B. A total of 13.68 million shares were traded on the day, compared to an average of 26.62M shares.
In the most recent transaction, Gibson Christopher sold 100,000 shares of RXRX for 4.84 per share on Aug 26 ’25. After the transaction, the Chief Executive Officer now owns 954,229 company shares. In a previous transaction on Aug 26 ’25, Gibson Christopher bought 100,000 shares at 4.84 per share.
Among the insiders who sold shares, Khan Najat disposed of 36,599 shares on Aug 18 ’25 at a per-share price of $5.52. This resulted in the Chief R&D Commercial Officer holding 668,197 shares of RXRX after the transaction. In another insider transaction, Khan Najat bought 36,599 shares at $5.52 per share on Aug 18 ’25.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, RXRX has a high of $12.36 and a low of $3.79.
As of this writing, RXRX has an earnings estimate of -$0.37 per share for the current quarter. EPS was calculated based on a consensus of 6.0 estimates, with a high estimate of -$0.24 per share and a lower estimate of -$0.45. The company reported an EPS of -$0.34 in the last quarter
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. RXRX’s latest balance sheet shows that the firm has $516.56M in Cash & Short Term Investments as of fiscal 2021. There were $11.48M in debt and $46.66M in liabilities at the time. Its Book Value Per Share was $2.12, while its Total Shareholder’s Equity was $542.94M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RXRX is Buy with a score of 3.33.
